Apyx Medical Corporation's Financial Performance in Comparison to Peers

Core Insights - Apyx Medical Corporation specializes in advanced energy solutions for surgical and medical applications, aiming to improve surgical outcomes in a competitive landscape with peers like Crinetics Pharmaceuticals, IDEAYA Biosciences, Harrow Health, Evelo Biosciences, and IRadimed Corporation [1] Financial Metrics - Apyx Medical's Return on Invested Capital (ROIC) is -26.00%, significantly lower than its Weighted Average Cost of Capital (WACC) of 11.53%, indicating inefficiency in capital utilization [2] - The ROIC to WACC ratio for Apyx is -2.26, further emphasizing its inability to generate sufficient returns to cover its cost of capital [2] - Crinetics Pharmaceuticals has a ROIC of -34.46% and a WACC of 4.90%, resulting in a ROIC to WACC ratio of -7.04, indicating similar struggles in capital efficiency [3] - IDEAYA Biosciences shows a ROIC of -38.96% against a WACC of 4.52%, leading to a ratio of -8.61, reflecting its challenges in generating returns above its cost of capital [3] - Harrow Health has a ROIC of 4.90% and a WACC of 5.87%, resulting in a ROIC to WACC ratio of 0.83, indicating returns just below its cost of capital [4] - Evelo Biosciences has a severely negative ROIC of -201.37% compared to its WACC of 9.04%, with a ratio of -22.28, showcasing extreme inefficiency [4] - IRadimed Corporation stands out with a ROIC of 19.35% and a WACC of 8.44%, resulting in a ROIC to WACC ratio of 2.29, indicating effective capital utilization and strong returns above its cost of capital [5]